Nintedanib and ovarian cancer: standardise surgery in trials?
Mené sur 1 366 patientes atteintes d'un cancer avancé de l'ovaire récemment diagnostiqué, cet essai randomisé de phase III évalue l'efficacité, du point de vue de la survie sans progression, et la toxicité de l'ajout de nintédanib à une chimiothérapie combinant carboplatine et paclitaxel
The enthusiasm for anti-angiogenic drug treatment of ovarian cancer has been somewhat thwarted by the minimal effect the addition of such drugs has had on survival. The main target has been VEGF, and one explanation for poor efficacy is the compensatory effect of other pathways after inhibition of the VEGF receptor. In The Lancet Oncology, Andreas Du Bois and colleagues address this important element of treatment in a phase 3 randomised trial of the addition of nintedanib versus placebo in first-line chemotherapy incorporating carboplatin and paclitaxel.
The Lancet Oncology , commentaire, 2014